Shares of Uniqure NV (NASDAQ:QURE) were down 11% during trading on Wednesday . The stock traded as low as $22.25 and last traded at $22.36. Approximately 729,774 shares were traded during mid-day trading, an increase of 85% from the average daily volume of 393,799 shares. The stock had previously closed at $25.11.
Several analysts have recently commented on QURE shares. HC Wainwright set a $35.00 price objective on Uniqure and gave the stock a “buy” rating in a research note on Tuesday, February 20th. Zacks Investment Research raised Uniqure from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday, February 6th. BidaskClub raised Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, Janney Montgomery Scott started coverage on Uniqure in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Uniqure currently has a consensus rating of “Buy” and an average price target of $20.75.
The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64. The stock has a market capitalization of $708.45, a PE ratio of -7.39 and a beta of 0.09.
In related news, insider Christian Klemt sold 5,093 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total transaction of $102,522.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deventer Sander Van sold 5,985 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $18.53, for a total value of $110,902.05. The disclosure for this sale can be found here. Insiders have sold 41,510 shares of company stock valued at $815,776 over the last ninety days. 0.73% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of QURE. SG Americas Securities LLC purchased a new stake in shares of Uniqure during the fourth quarter valued at approximately $119,000. Ellington Management Group LLC bought a new position in Uniqure during the fourth quarter valued at $237,000. Goldman Sachs Group Inc. bought a new position in Uniqure during the fourth quarter valued at $373,000. Virtus Fund Advisers LLC bought a new position in Uniqure during the fourth quarter valued at $389,000. Finally, OxFORD Asset Management LLP bought a new position in Uniqure during the third quarter valued at $399,000. 44.05% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/16/uniqure-qure-trading-down-11.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.